These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 38438052)
1. Toll-like receptor signalling as a cannabinoid target. Cui Sun M; Otálora-Alcaraz A; Prenderville JA; Downer EJ Biochem Pharmacol; 2024 Apr; 222():116082. PubMed ID: 38438052 [TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis. Fitzpatrick JK; Downer EJ Neuropharmacology; 2017 Feb; 113(Pt B):618-626. PubMed ID: 27079840 [TBL] [Abstract][Full Text] [Related]
3. Cannabinoids and innate immunity: taking a toll on neuroinflammation. Downer EJ ScientificWorldJournal; 2011 Apr; 11():855-65. PubMed ID: 21479354 [TBL] [Abstract][Full Text] [Related]
4. The neurobiology and evolution of cannabinoid signalling. Elphick MR; Egertová M Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486 [TBL] [Abstract][Full Text] [Related]
5. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. Brunt TM; Bossong MG Eur J Neurosci; 2022 Feb; 55(4):909-921. PubMed ID: 32974975 [TBL] [Abstract][Full Text] [Related]
7. An overview on the biochemistry of the cannabinoid system. Gómez-Ruiz M; Hernández M; de Miguel R; Ramos JA Mol Neurobiol; 2007 Aug; 36(1):3-14. PubMed ID: 17952645 [TBL] [Abstract][Full Text] [Related]
9. Phytocannabinoids and endocannabinoids. Fisar Z Curr Drug Abuse Rev; 2009 Jan; 2(1):51-75. PubMed ID: 19630737 [TBL] [Abstract][Full Text] [Related]
10. Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Hiley CR; Ford WR Biol Rev Camb Philos Soc; 2004 Feb; 79(1):187-205. PubMed ID: 15005177 [TBL] [Abstract][Full Text] [Related]
11. CB receptor ligands from plants. Woelkart K; Salo-Ahen OM; Bauer R Curr Top Med Chem; 2008; 8(3):173-86. PubMed ID: 18289087 [TBL] [Abstract][Full Text] [Related]
12. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Pertwee RG Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283 [TBL] [Abstract][Full Text] [Related]
13. Cannabinoids and the gut: new developments and emerging concepts. Izzo AA; Sharkey KA Pharmacol Ther; 2010 Apr; 126(1):21-38. PubMed ID: 20117132 [TBL] [Abstract][Full Text] [Related]
14. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Pertwee RG Expert Opin Investig Drugs; 2000 Jul; 9(7):1553-71. PubMed ID: 11060760 [TBL] [Abstract][Full Text] [Related]
15. Cannabinoids. Grotenhermen F Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):507-30. PubMed ID: 16266285 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic Use of Synthetic Cannabinoids: Still an OpenIssue? De Luca MA; Fattore L Clin Ther; 2018 Sep; 40(9):1457-1466. PubMed ID: 30180974 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of the endocannabinoid system in the brain. Ramos JA; González S; Sagredo O; Gómez-Ruiz M; Fernández-Ruiz J Mini Rev Med Chem; 2005 Jul; 5(7):609-17. PubMed ID: 16026307 [TBL] [Abstract][Full Text] [Related]
20. Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation. McCoy KL Mediators Inflamm; 2016; 2016():5831315. PubMed ID: 27597805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]